Skip to main content

Table 4 Point estimates of the incremental cost-effectiveness ratios (ICER) for PoC testing per patient maintained in the target range* compared with laboratory testing

From: The cost-effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial

Test

Treatment Group

Costs per patient ($)

Effects per patient *

ICER ($)

INR

Intervention (PoCT)

3,298

0.5701

 
 

Control (Laboratory)

3,150

0.6147

 
 

Difference

148

-0.0446

Dominated

HbA1c

Intervention (PoCT)

3,676

0.6548

 
 

Control (Laboratory)

3672

0.5618

 
 

Difference

4

0.0930

$40

ACR

Intervention (PoCT)

1,727

0.7739

 
 

Control (Laboratory)

1,954

0.7418

 
 

Difference

-228

0.0321

Dominant

Lipids

Intervention (PoCT)

2,732

0.1592

 
 

Control (Laboratory)

2,202

0.1066

 
 

Difference

530

0.0526

$10,082

  1. *Effect is the proportion of patients in target range as determined at the end of the Trial (18 months mean observation time)